HCA’s latest deals on pause by FTC

The Federal Trade Commission (FTC) has filed suit to block the acquisition of Steward Health Care System by HCA Healthcare

The news comes just after HCA Healthcare was hit with a second antitrust lawsuit for anti-competitive actions. The healthcare company owns more than 70% of market share in seven counties in North Carolina, and its monopoly has led to higher healthcare prices and lower quality of care for residents, the lawsuit alleges. 

HCA is a Nashville, Tennessee-based for-profit healthcare system with 182 hospitals in the United States and abroad, while Steward Health is a for-profit healthcare system headquartered in Dallas, Texas, with 41 hospitals in the U.S. and abroad. According to the FTC, the acquisition would eliminate the second and fourth largest healthcare systems in the Wasatch Front region, where 80% of Utah residents live.

“As the second and fourth largest healthcare systems in the Wasatch Front region of Utah, which surrounds Salt Lake City, HCA Healthcare and Steward Health Care System help to keep costs down for consumers by competing vigorously with each other,” FTC Bureau of Competition Director Holly Vedova said in a statement. “The result is lower prices and more innovative services for patients and their families. If these companies merge, this competition will be lost, and Steward will no longer be available to patients as a low-cost provider in this region.”

In its complaint, the FTC also named HCA Healthcare CEO Ralph de la Torre, MD. The complaint alleges the deal would reduce the number of healthcare systems offering inpatient general acute care hospital services, bringing the number down from three to two health systems in some counties. It would also eliminate Steward as a low-cost competitor in the region for HCA Healthcare, and increase market concentration levels significantly.

The FTC voted to seek a temporary restraining order to block the deal 5-0. The federal court complaint and request for preliminary relief will be filed in the U.S. District Court for the District of Utah to halt the transaction pending an administrative proceeding, and the administrative trial is scheduled to begin on Dec. 13, 2022.

 

Related Healthcare System Merger Content:

Dartmouth, GraniteOne merger is dead

FTC receives support––and pushback––for interfering in hospital merger

FTC plans to kill a hospital merger

FTC files suit to stop Illumina’s $7.1B takeover of life sciences firm

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.